Charles Schwab Investment Management Inc. Trims Stock Position in Embecta Corp. $EMBC

Charles Schwab Investment Management Inc. cut its stake in Embecta Corp. (NASDAQ:EMBC) by 6.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 735,087 shares of the company’s stock after selling 47,103 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.26% of Embecta worth $9,372,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Jefferies Financial Group Inc. increased its position in shares of Embecta by 60.1% during the first quarter. Jefferies Financial Group Inc. now owns 573,000 shares of the company’s stock valued at $7,306,000 after buying an additional 215,000 shares during the period. Wealthquest Corp purchased a new position in shares of Embecta during the 1st quarter worth approximately $48,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in shares of Embecta in the 1st quarter worth approximately $312,000. Picton Mahoney Asset Management purchased a new position in shares of Embecta in the 1st quarter valued at approximately $50,000. Finally, Mackenzie Financial Corp boosted its position in shares of Embecta by 72.5% during the first quarter. Mackenzie Financial Corp now owns 70,652 shares of the company’s stock valued at $901,000 after purchasing an additional 29,696 shares in the last quarter. 93.83% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on EMBC shares. Mizuho decreased their price objective on Embecta from $13.00 to $12.00 and set a “neutral” rating for the company in a report on Wednesday, July 16th. BTIG Research set a $25.00 target price on shares of Embecta and gave the stock a “buy” rating in a research report on Friday, May 23rd. Finally, Wall Street Zen raised shares of Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $19.00.

Embecta Trading Down 0.8%

Embecta stock opened at $14.26 on Tuesday. Embecta Corp. has a 12 month low of $9.20 and a 12 month high of $21.48. The stock has a fifty day simple moving average of $11.04 and a two-hundred day simple moving average of $11.94. The firm has a market cap of $834.07 million, a price-to-earnings ratio of 9.97, a PEG ratio of 0.80 and a beta of 1.08.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Friday, August 8th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.77 by $0.35. Embecta had a negative return on equity of 23.40% and a net margin of 7.58%.The company had revenue of $295.50 million for the quarter, compared to analysts’ expectations of $278.15 million. During the same period last year, the firm posted $0.74 earnings per share. Embecta’s revenue was up 8.4% compared to the same quarter last year. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. On average, equities research analysts forecast that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 15th. Stockholders of record on Friday, August 29th will be issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 4.2%. The ex-dividend date of this dividend is Friday, August 29th. Embecta’s payout ratio is presently 41.96%.

Embecta Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.